BRAF and melanoma: Le Mercier et al. proved that VISTA inhibitors significantly reduced growth in many solid tumor models (B16/OVA melanoma, B16/BL6 melanoma, MB49 bladder carcinoma, and PTEN/BRAF inducible melanoma) regardless of their immunogenic status or origin [7].